Literature DB >> 17032134

Inhibition of the ubiquitin-proteasome system: a new avenue for atherosclerosis.

Chunjiang Tan1, Yuguang Li, Xuerui Tan, Hongxin Pan, Wen Huang.   

Abstract

BACKGROUND: The ubiquitin-proteasome system (UPS) is thought to be functionally active in atherosclerosis (AS) lesions. Aspirin was found to be a potent inhibitor of the UPS in some tumour studies; however, its effect on AS remains to be demonstrated in vivo.
METHODS: New Zealand rabbits were placed on a normal diet (N) or on a normal diet with aspirin (NI) or on an atherogenic diet without (H) or with aspirin (HI) for 12 weeks. Proteasome activity, concentrations of plasma lipids and levels of peroxidation were determined. Ubiquitin/ubiquitin-conjugates (Ub), IkappaBalpha, phosphorylated IkappaB (pIkappaBalpha) and p65 were investigated by Western blotting or immunochemistry.
RESULTS: Concentrations of plasma lipids and peroxidation levels were higher in H or HI vs. N or NI. Histological analysis showed that atheroma was increased in H. Ub and IkappaBalpha were mainly localised in subendothelium and media vascular smooth muscle cells. Western blots revealed that Ub, IkappaBalpha, and pIkappaBalpha were increased, whereas p65 was lower in HI vs. H. The activity of the 20S proteasome was functionally active in H vs. N, NI or HI, while the 26S proteasome was not affected in any of the groups.
CONCLUSIONS: Aspirin can attenuate the pathogenesis of atheroma formation, the degradation of IkappaBalpha and pIkappaBalpha, and lower the expression of p65, indicating that its therapeutic effects on AS may be via inhibition of the UPS.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17032134     DOI: 10.1515/CCLM.2006.209

Source DB:  PubMed          Journal:  Clin Chem Lab Med        ISSN: 1434-6621            Impact factor:   3.694


  6 in total

Review 1.  Sent to destroy: the ubiquitin proteasome system regulates cell signaling and protein quality control in cardiovascular development and disease.

Authors:  Monte S Willis; W H Davin Townley-Tilson; Eunice Y Kang; Jonathon W Homeister; Cam Patterson
Journal:  Circ Res       Date:  2010-02-19       Impact factor: 17.367

Review 2.  The ubiquitin-proteasome system and cardiovascular disease.

Authors:  Saul R Powell; Joerg Herrmann; Amir Lerman; Cam Patterson; Xuejun Wang
Journal:  Prog Mol Biol Transl Sci       Date:  2012       Impact factor: 3.622

Review 3.  On to the road to degradation: atherosclerosis and the proteasome.

Authors:  Joerg Herrmann; Lilach O Lerman; Amir Lerman
Journal:  Cardiovasc Res       Date:  2009-10-08       Impact factor: 10.787

Review 4.  Scientific research at Fujian Academy of Integrative Medicine: current status and future directions.

Authors:  Xian-xiang Liu; Jin-zhong Wu; Yan-ping Lin; Zhi-yun Cao; Jun Peng; Jing Cai; Chun-jiang Tan; Lian-ming Liao; Jian Du
Journal:  Chin J Integr Med       Date:  2011-09-11       Impact factor: 1.978

Review 5.  Dysfunction of the ubiquitin-proteasome system in atherosclerotic cardiovascular disease.

Authors:  Feilong Wang; Amir Lerman; Joerg Herrmann
Journal:  Am J Cardiovasc Dis       Date:  2015-03-10

6.  Changes in expression of proteasome in rats at different stages of atherosclerosis.

Authors:  Fadil Oenzil; Eti Yerizel
Journal:  Anat Cell Biol       Date:  2016-06-24
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.